Roche expands cell therapy portfolio with Poseida acquisition
Published: Tuesday, Nov 26th 2024, 08:40
Retour au fil d'actualité
Roche is strengthening its research pipeline with the acquisition of the US company Poseida Therapeutics. For a total of around 1.5 billion US dollars, the Basel-based company is bringing an expert in the field of personalized CAR-T cell therapies on board.
Poseida's research and development portfolio includes preclinical and clinical standard CAR-T therapies in various therapeutic areas, including blood cancers, tumors and autoimmune diseases, as well as manufacturing capabilities and technology platforms, according to a Roche announcement on Tuesday.
The acquisition builds on the existing partnership between Roche and Poseida, which was entered into in 2022 under a collaboration and license agreement and focused on the development of ready-to-use CAR-T cell therapies for the treatment of patients with blood cancer.
The aim now is to develop the next generation of commercially available CAR-T cell therapies with increased efficacy and favorable safety on a scale that could potentially reach more patients and enable broad commercial use.
According to a press release issued on Tuesday, Roche expects to complete the transaction in the first quarter of 2025. Specifically, the Basel-based company is offering USD 9.00 per Poseida Therapeutics share in cash. In addition, shareholders are to receive a non-tradable contingent value right (CVR) of up to USD 4.00 per share in cash.
©Keystone/SDA
French 
English 
German 
Spanish 
Arabic